Add a New Bulls Reason

Company: Hemispherx BioPharma (HEB)
Current price:
Headline: (100 character max)
Analysis:
Cancel
77%
agree
9 votes

  FDA Approval

If HEB get FDA approval in the next weeks the stock will range between $10-$30 from its current $3 range. I personally purchased last week at $2.65 and thought I was in a little late. But if FDA approval fails the stock could fall below $1.

(100 character max) Cancel
0%
agree
0 votes

  FDA Approval not needed to move this stock

Ampligen has application for H1N1 and should that be confirmed this stock will jump.

(100 character max) Cancel
0%
agree
0 votes

  Hemispherx (AMEX:HEB) Seeks Rebound: Phase 6 Flu Pandemic

With the World Health Organization (WHO) officially declaring the flu a pandemic of phase 6, one company looking to make waves is Hemispherx BioPharma (AMEX:HEB). Analysis from http://www.StocksHaven.com

Hemispherx has recently been in limbo awaiting FDA decision on the long-awaited treatment for Chronic Fatigue Syndrome (CFS), Ampligen.

Ampligen, also known as poly I:poly C12U, is an experimental immunomodulatory double stranded RNA drug developed by HEMISPHERx Biopharma of Philadelphia, Pennsylvania. Ampligen was first synthesized in the 1970s and has been proposed and tested as a treatment for many illnesses, but primarily chronic fatigue syndrome (ME/CFS) and acquired immunodeficiency syndrome (AIDS).

Summary of articles

Identifying Fact vs. Fiction on Hemispherx’s Ampligen

Hemispherx Ampligen Combats H5N1

Post Approval Hemispherx Ampligen PPS Evaluation

Conference Call - Hemispherx Responds to TheStreet.com

Hemispherx Fights Back Against Feuerstein

Conference Call - Hemispherx BioPharma, Inc.

Taking on influenza

Hemispherx has a broad-based technology platform for confronting the potential of an influenza pandemic, which consists of both preventative (vaccine) components as well as experimental therapeutic interventions. Clinical results from trials conducted in Australia are being evaluated and major vaccine initiatives in Japan are being accelerated in collaboration with the Japanese National Institutes of Health and the Japanese Ministry of Health. According to the Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma’s Drug Technology as the “Most Promising Mucosal Adjuvant for Influenza.”

StocksHaven Investments believes the phase 6 declaration presents a strong buy signal for Hemispherx BioPharma (AMEX:HEB), within both the short-term and long-term.

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki